Dare Bioscience, Inc. current report, 10 November 2026

Filing Summary

Company: Daré Bioscience, Inc. Filing: Form 8-K, reporting a special stockholders’ meeting held November 10, 2026; filed November 12, 2026.

Business Context and Results

The filing reports stockholder votes, not quarterly or annual financial results. It provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no financial comparison or guidance.

ProposalForAgainstAbstentionsOutcome
Approval under Nasdaq listing rules of potential future issuance of common stock upon exercise of outstanding warrants5,320,5152,369,55438,382Approved
Adjournment, if needed, to solicit additional votes for Proposal 15,364,0042,311,40853,039Approved; adjournment was not necessary

Key Implications and Items to Verify

  • Stockholders approved the potential future issuance of shares upon exercise of outstanding warrants. This vote does not itself indicate that shares were issued or warrants exercised.
  • The filing does not specify the number of shares potentially issuable, warrant terms, exercise timing, or resulting dilution; review the proxy statement filed October 6, 2026, and related disclosures for those details.
  • No material financial changes, outlook, risks, or contingencies are described in this filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.